600276 Jiangsu Hengrui Pharmaceuticals
- 44.75
- +0.06+0.13%
Jiangsu Hengrui Pharmaceuticals News
The company left the pipeline, capital paid, Hengrui Pharmaceutical's GLP-1 innovative drug team up to go overseas
Hengrui's overseas strategy and style of play seem to be evolving.
Express News | Hengrui Pharmaceutical: Received a complete response letter from the US FDA regarding injectable carelizumab
Hong Kong Stock Concept Tracking | Hengrui Pharmaceutical's GLP-1 Products Achieve Active Layout for Foreign Authorized Domestic and Foreign Companies (with Concept Shares)
The wave of research and development of GLP-1 drugs continues to heat up as market demand increases and the development of new drugs advances
Creating a new model for going overseas? Hengrui packaged the GLP-1 product portfolio and reached a major BD deal with a US company
① Tonight, Hengrui Pharmaceutical announced that it reached a BD deal with a special company set up by several capital institutions in the US in May; ② The deal not only involved huge down payments and subsequent milestone payments and sales shares, but also included nearly 20% of the US company's shares; ③ The industry believes that Hengrui Pharmaceutical is joining forces with capital to create a new model for innovative drugs to go overseas, which can achieve a win-win situation for all parties, which is very novel.
Hengrui Pharmaceutical (600276.SH): Plans to license the GLP-1 product portfolio to Hercules of the United States for a fee
GLONGHUI May 16 丨 Hengrui Pharmaceutical (600276.SH) announced that the company will license the GLP-1 product portfolio with independent intellectual property rights to Hercules of the United States for a fee, and Hercules of the United States will obtain the exclusive right to develop, produce and commercialize the GLP-1 product portfolio on a global scale other than Greater China. As part of the consideration for the foreign licensing transaction, Hengrui will acquire 19.9% of the shares in Hercules of the United States and will obtain licensing fees for the GLP-1 product portfolio from Hercules of the United States. GLP-1 product portfolio
Hengrui Pharmaceuticals Plans Up to 1.2 Billion Yuan Share Buyback
Jiangsu Hengrui Pharmaceuticals (SHA:600276) plans to spend between 600 million yuan and 1.2 billion yuan to buy back shares, according to a filing with the Shanghai Stock Exchange. The repurchased sh
Express News | Hengrui Pharmaceutical: Will acquire 19.9% of the shares of Hercules in the United States
Hengrui Pharmaceutical (600276.SH): A total cost of 635 million yuan to buy back 0.22% of the shares
Gelonghui, May 15, 丨 Hengrui Pharmaceutical (600276.SH) announced that on May 14, 2024, the company's share repurchase period expired. The actual share repurchase was 14,351,878 shares, accounting for 0.22% of the company's total share capital. The highest transaction price was 47.01 yuan/share, and the minimum transaction price was 41.09 yuan/share. The average repurchase price was about 44.22 yuan/share, and the total transaction amount was 634,665,849.66 yuan (excluding transaction fees).
On May 15, A50ETF Huabao (159596) closed down 0.78% with a turnover of 154 million yuan. In terms of constituent stocks, only the Midea Group rose 2.8%. BYD fell 2.57%, Hengrui Pharmaceuticals fell 1.46%, CITIC Securities fell 1.37%, and all other individ
On May 15, A50ETF Huabao (159596) closed down 0.78% with a turnover of 154 million yuan. In terms of constituent stocks, only the Midea Group rose 2.8%. BYD fell 2.57%, Hengrui Pharmaceuticals fell 1.46%, CITIC Securities fell 1.37%, and all other individual stocks turned green. According to the news, the excellent performance of the recent A-share industry leading quarterly report became the focus of the market. The 2024 A-share industry leading quarterly report showed impressive performance, with 26 companies that achieved year-on-year growth in both revenue and net profit, accounting for more than 50%. China Merchants Securities's latest research report points out that this year's quarterly report confirmed the decline in the growth rate and freedom of A-share capital expenditure
Hengrui Pharmaceuticals Unit Gets China Clinical Trial Approval for Kidney Medication
China's medical products administrator approved Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Guangdong Hengrui Pharmaceutical's clinical trial for its SHR-2173 injection, according to a Wednesday
Hengrui Pharmaceutical (600276.SH): SHR-2173 injection received a notice of approval for drug clinical trials
Hengrui Pharmaceutical (600276.SH) announced that Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received the State Drug Administration...
Express News | Hengrui Pharmaceutical: Subsidiary obtains approval notice for drug clinical trials
Hehuang Pharmaceutical (00013.HK) and Hengrui Pharmaceutical reached a cooperation and initiated a phase II/III study on surufatinib (surufatinib) combined with camrelizumab (camrelizumab) in the treatment of primary pancreatic ductal adenocarcinoma
Gelonghui, May 14, 丨 Hehuang Pharmaceutical (00013.HK) announced the launch of a Chinese phase II/III clinical trial today to evaluate Hehuang Pharmaceutical's drug candidate surufatinib (surufatinib), the PD-1 antibody camrelizumab (camrelizumab) of Jiangsu Hengrui Pharmaceutical Co., Ltd. (“Hengrui Pharmaceutical”), albumin-conjugated paclitaxel (nab-paclitaxel), and gemcitabine (gemcitabine) for first-line treatment of metastatic pancreatic conduction Ductal adenocarcinoma (PDAC) patients
On May 9, A50ETF Huabao (159596) closed up 0.99% with a turnover of 224 million yuan. In terms of constituent stocks, the top 10 largest stocks rose, Ningde Times rose 3.04%, Midea Group rose 1.55%, Zijin Mining rose 1.49%, Hengrui Pharmaceutical rose 1.0
On May 9, A50ETF Huabao (159596) closed up 0.99% with a turnover of 224 million yuan. In terms of constituent stocks, the top 10 largest stocks rose, Ningde Times rose 3.04%, Midea Group rose 1.55%, Zijin Mining rose 1.49%, Hengrui Pharmaceutical rose 1.03%, China Ping An rose 0.93%, BYD rose 0.85%, China Merchants Bank rose 0.78%, and Changjiang Electric Power rose 0.2%. CICC research indicates that under the macroeconomic combination of improving China's growth expectations and global capital reallocation, the A-share recovery market is expected to continue the current attractive growth style and division of valuations
Hengrui Pharma's Unit Gets Regulatory Nod to Trial HRS-5965 Capsules
China's National Medical Products Administration approved Jiangsu Hengrui Pharmaceuticals' (SHA:600276) unit, Chengdu Shengdi Pharmaceutical's application to conduct clinical trials on HRS-5965 capsul
Illustration丨Capital from North China bucked the trend and added positions to Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare
The net sale of A-shares today was 4,044 billion yuan, the second consecutive day of net sales. Among them, Ping An Bank, Guodian Nanrui, and Zhongji Xuchuang received net sales of 255 million yuan, 242 million yuan, and 204 million yuan respectively; Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare bucked the trend and received net purchases of 395 million yuan, 299 million yuan, and 221 million yuan respectively. According to statistics, the capital from North China has been increasing Kweichow Moutai for 3 consecutive days, for a total of 4.265 billion yuan.
Express News | Hengrui Pharmaceutical: The subsidiary HRS5580 for injection obtained a notice of approval for clinical trials of the drug
Hengrui Pharmaceutical (600276.SH): cumulative repurchase of 0.22% of shares
Gelonghui, May 6, 丨 Hengrui Pharmaceutical (600276.SH) announced that as of April 30, 2024, the company had repurchased a total of 14,351,878 shares through centralized bidding transactions, accounting for 0.22% of the company's total share capital. The highest transaction price was 47.01 yuan/share, the lowest price was 41.09 yuan/share, and the total amount paid was 634,665,849.66 yuan (excluding transaction fees).
Express News | Hengrui launches GLP-1R/GIPR dual agonist weight loss phase III study
Hengrui Pharmaceutical (600276): Steady recovery in performance, fruitful transformation and innovation
Recently, the company released reports for the first quarter of 2023 and 2024. In 2023, the company's revenue was 22.82 billion yuan (+7.26% year over year), of which innovative drug revenue was 10.637 billion yuan
Analysis
Price Target
No Data
